Very encouraging, but approval will take timeFinally we got some meat on the bone. Why did they wait six months to provide more clarity on efficacy related to stable disease. Why did they not tell us that some patients took the drug, stoped it and their cancer were stable for a long time afterward. It seems that they have a approvable drug based on progression free survival criteria, but it will take time to achieve that. It won't be a fast track approval. Also, it seems potential for combination therapy is high, also potential to develop other PDCs. Their problem now is money. They need to sell this story in a much better way. Also, potential for partnership is high because they need the money. Takeovers are rare in biopharmas/biotechs, but they clearly are a cheap target.